BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the Covid-19 pipeline. The team has investigated each drug as to original inventor (company/country), mechanism of action, and strategic approach, as well as de-duplicated programs for the same active ingredient (for example, hydroxychloroquine is counted only once). This data will be updated weekly on Monday mornings.

The data below shows two key things:

Biopharma companies - particularly small biotech companies - are undertaking a monumental campaign to combat, and hopefully eradicate, Covid-19.

Innovation is being led by U.S.-based companies.

TAKE AWAYS AS OF 12 MAY 2020:

430 unique compounds are in development:

-100 of them are vaccines.

-135 are antivirals.

-195 are treatments.

Most are in Phase 2 development.

207 of them are being developed in the U.S.A.

The list is located here: https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus/therapeutic-development/bio-covid-19-therapeutic-development-tracker